Overview

* Alvotech's ( ALVO ) nine-month revenue rose 24% to $420 mln, driven by product and service growth

* Nine months Adjusted EBITDA fell 21% due to higher R&D investments and lower licensing revenues

* Company revised full-year revenue outlook to $570 mln-$600 mln, adj EBITDA to $130mln-$150 mln,

Outlook

* Alvotech ( ALVO ) revises full-year revenue outlook to $570 mln-$600 mln

* Company expects adjusted EBITDA of $130-$150 mln for 2025

* Alvotech anticipates strong growth in 2026 with Q4 2025 launches

Result Drivers

* PRODUCT REVENUE GROWTH - Alvotech's ( ALVO ) product and service revenue increased 85% due to the commercial expansion of AVT02 and AVT04

* LICENSE REVENUE DECLINE - License and other revenue decreased 13% due to fewer strategic milestone achievements compared to 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

9M Net $136.47

Income mln

9M $29.95

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Alvotech SA ( ALVO ) is $10.00, about 44.2% above its November 11 closing price of $5.58

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)